Analysts' Actions: BBBY DAN JCI KORS X

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Apache was upgraded to buy at TheStreet Ratings.

Bed, Bath & Beyond was downgraded at Canaccord Genuity to hold from buy. $84 price target. Company could be hurt by a challenging consumer discretionary environment, Canaccord Genuity said.

Biogen Idec was initiated with a market perform rating at FBR Capital Markets. $259 price target. Company has limited visibility with its hemophilia franchises, FBR Capital Markets said.

Corporate Executive Board was downgraded to hold at TheStreet Ratings.

Dana was downgraded at Keybanc to hold from buy. Valuation call, as little new business growth is expected in 2014.

Edwards Lifesciences downgraded at J.P. Morgan to underweight from neutral. $62 price target. Street estimates too high and growth deceleration to start in the second half of 2014.

First Republic was downgraded at Deutsche Bank to hold. Valuation call, as the stock is up 53% since January, Deutsche Bank said.

Johnson Controls was downgraded at Litchfield Hills to hold from buy. Valuation call, based on a $47 price target, Litchfield Hills said.

Michael Kors was initiated with a buy rating at Maxim Group. $99 price target. Company can continue to grow over the coming years, Maxim Group said.

Oceaneering was upgraded at Howard Weil to outperform from sector perform. $105 price target. Company has solid visibility and boosted guidance, Howard Weil said.

SM Energy was upgraded at Topeka Capital to buy from hold. $120 price target. Company disclosed new acreage in the Permian basin, Topeka Capital said.

SanDisk was downgraded at Bank of America/Merrill Lynch to neutral from buy. Valuation call, based on a $75 price target, BofA/Merrill Lynch said.

Union Pacific was downgraded at Robert Baird to neutral from outperform. $173 price target. Stock is largely factoring in strong pricing, Baird said.

US Steel was downgraded at Deutsche Bank to hold from buy. $22 price target. Company offered a weaker outlook, despite better steel market trends, Deutsche Bank said.

Xylem was downgraded at Keybanc to hold from buy. Valuation call, following the recent surge in the stock, Keybanc said.

Xylem was upgraded at DA Davidson to neutral from underperform. $34 price target. Company boosted its guidance and announced surprise growth, DA Davidson said.

Stock Comments/EPS Changes

Acadia Healthcare numbers, price target were raised at Jefferies. Shares are now seen reaching $47. Strong top-line growth and upside in margin expansion, Jefferies said. Estimates lifted into next year. Buy rating.

Actavis estimates, price target were increased at Jefferies. Company expects double-digit organic growth after in-line third-quarter results. $168 price target and hold rating.

Archer-Daniels-Midland numbers were increased at BMO Capital. Estimates were boosted through 2014. Company is seeing higher divisional profits and a higher LIFO benefit, BMO Capital said. Market perform rating and new $42 price target.

Aetna estimates, price target were lowered at BMO Capital. Estimates were cut through 2014. Company reduced its guidance, BMO Capital said. Outperform rating and new $70 price target.

Ameriprise estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $100. Estimates were also increased, given better asset management growth, Credit Suisse said. Neutral rating.

Cummins estimates, price target were reduced at BMO Capital. Shares are now seen reaching $144. Estimates were also cut, given the company's new guidance, BMO Capital said. Outperform rating.

Dana estimates, price target are lowered at Jefferies. Weakness in commercial vehicles, Jefferies said. $23 price target and buy rating.

Gilead estimates, price target were increased at Credit Suisse. Estimates were raised through 2015. Company is seeing higher sales and keeping a tight lid on costs, Credit Suisse said. Outperform rating and new $80 price target.

Gilead Sciences price target was raised at J.P. Morgan to $85. Strong third-quarter with upside in HIV-related sales, J.P. Morgan said. Overweight rating.

L-3 Communications estimates, price target were raised at Credit Suisse. Price target was increased to $97. Estimates were also increased, as the company is realizing higher margins.

LinkedIn estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $288. Estimates were also increased, given the company's new guidance. Outperform rating.

Questcor Pharmaceuticals estimates, price target were increased at Jefferies. QCOR raised its numbers, said Jefferies. Very robust Acthar growth in rheumatology, Jefferies also said. $76 price target and buy rating.

Titan International estimates, price target were lowered at Jefferies. TWI decreased its numbers into next year. Uncertainty reflecting commodity end markets and company execution, Jefferies said. $16 price target and Hold rating.

Valero estimates, price target were raised at Credit Suisse. Shares are now seen reaching $40. Crude spreads have widened, Credit Suisse said. Neutral rating.

Vertex estimates, price target were cut at Credit Suisse. Shares are now seen reaching $78. Estimates were also reduced, given lower Incivek sales, Credit Suisse said. Neutral rating.

Western Union numbers were cut at Sterne Agee. Shares are now seen reaching $20. Estimates were also reduced, given the company's new guidance, Sterne Agee said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.

View Comments (0)

Recommended for You